We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KGF:LSEKingfisher Plc Analysis

Data as of 2026-03-14 - not real-time

£308.60

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Kingfisher’s price sits just above a clearly identified support level, while the short‑term moving average sits above the mid‑term average, suggesting a bullish alignment. The 14‑day RSI is in oversold territory, indicating potential upside momentum, yet the MACD presents a bearish divergence, warning of possible short‑term weakness. Volume is on an upward trend, reinforcing the credibility of recent price moves.
Fundamentally, the company shows modest revenue growth and thin profit margins, with a low return on equity and assets that point to limited operational efficiency. The discounted cash‑flow model places fair value well above the current market price, implying an undervalued scenario, but the price‑to‑book multiple is extraordinarily high, raising concerns about balance‑sheet valuation.
Dividend yield appears attractive, however the payout ratio exceeds one hundred percent, casting doubt on the sustainability of the current dividend policy. The stock’s beta is low, indicating limited market‑wide volatility, yet the recent 30‑day price swing is pronounced, reflecting sector‑specific risk. Investors should weigh the technical upside potential against the fundamental constraints and dividend sustainability issues before deciding on exposure.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Oversold RSI suggesting near‑term bounce
  • Support level just below current price
  • Rising volume confirming buying interest

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • DCF‑derived fair value indicates upside
  • High dividend payout ratio raises sustainability concerns
  • Modest revenue growth and thin margins limit earnings expansion

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Elevated price‑to‑book multiple questions long‑term valuation
  • Low ROE and ROA suggest limited competitive advantage
  • Strategic shift toward e‑commerce may improve margins over time

Key Metrics & Analysis

Financial Health

Revenue Growth0.80%
Profit Margin1.44%
P/E Ratio30.9
ROE2.86%
ROA3.55%
Debt/Equity37.15
P/B Ratio85.7
Op. Cash Flow£1.4B
Free Cash Flow£867.5M

Technical Analysis

TrendBullish
RSI29.3
Support£302.40
Resistance£372.30
MA 20£345.31
MA 50£337.12
MA 200£299.59
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair Value£623.74
Target Price£314.07
Upside/Downside1.77%
GradeUndervalued
TypeValue
Dividend Yield4.02%

Risk Assessment

Beta0.26
Volatility30.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.